Connor Clark & Lunn Investment Management Ltd. Purchases 3,573 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Connor Clark & Lunn Investment Management Ltd. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,532 shares of the biotechnology company's stock after buying an additional 3,573 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in United Therapeutics were worth $5,127,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. MassMutual Private Wealth & Trust FSB raised its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp raised its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $131,000. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $388.25.

Remove Ads

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 116,464 shares of company stock worth $42,396,244. Company insiders own 11.90% of the company's stock.

United Therapeutics Price Performance

United Therapeutics stock traded down $5.15 during midday trading on Tuesday, reaching $317.79. 201,674 shares of the company traded hands, compared to its average volume of 442,994. The firm has a market capitalization of $14.27 billion, a price-to-earnings ratio of 13.95, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The business has a 50 day moving average of $349.12 and a two-hundred day moving average of $358.27. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 earnings per share. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.